243 related articles for article (PubMed ID: 19879012)
1. Treatment of advanced non-small-cell lung cancer in the elderly.
Gridelli C; Maione P; Rossi A; Ferrara ML; Castaldo V; Palazzolo G; Mazzeo N
Lung Cancer; 2009 Dec; 66(3):282-6. PubMed ID: 19879012
[TBL] [Abstract][Full Text] [Related]
2. Management of unfit older patients with advanced NSCLC.
Gridelli C; Maione P; Rossi A; Palazzolo G; Colantuoni G; Rossi E
Cancer Treat Rev; 2009 Oct; 35(6):517-21. PubMed ID: 19457617
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer in the elderly.
Gridelli C; Langer C; Maione P; Rossi A; Schild SE
J Clin Oncol; 2007 May; 25(14):1898-907. PubMed ID: 17488989
[TBL] [Abstract][Full Text] [Related]
5. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
7. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
8. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
Sandler A; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Herbst RS; Sandler A
Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
[TBL] [Abstract][Full Text] [Related]
10. Angiogenesis inhibition in the treatment of lung cancer.
Vokes E; Herbst R; Sandler A
Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
12. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel.
Gridelli C; Aapro M; Ardizzoni A; Balducci L; De Marinis F; Kelly K; Le Chevalier T; Manegold C; Perrone F; Rosell R; Shepherd F; De Petris L; Di Maio M; Langer C
J Clin Oncol; 2005 May; 23(13):3125-37. PubMed ID: 15860872
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib in non-small cell lung cancer treatment: current status and future development.
Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello F
Oncologist; 2007 Jul; 12(7):840-9. PubMed ID: 17673615
[TBL] [Abstract][Full Text] [Related]
16. Treating advanced non-small cell lung cancer in the elderly.
Maione P; Rossi A; Sacco PC; Bareschino MA; Schettino C; Ferrara ML; Falanga M; Ambrosio R; Gridelli C
Ther Adv Med Oncol; 2010 Jul; 2(4):251-60. PubMed ID: 21789138
[TBL] [Abstract][Full Text] [Related]
17. Current treatments for advanced stage non-small cell lung cancer.
Stinchcombe TE; Socinski MA
Proc Am Thorac Soc; 2009 Apr; 6(2):233-41. PubMed ID: 19349493
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
19. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
Langer C; Soria JC
Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
[TBL] [Abstract][Full Text] [Related]
20. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
Hirsh V
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S62-70. PubMed ID: 21885001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]